Research programme: Senolytic anti-ageing therapies - Ascentage Pharma/UNITY Biotechnology

Drug Profile

Research programme: Senolytic anti-ageing therapies - Ascentage Pharma/UNITY Biotechnology

Alternative Names: UBX-0101

Latest Information Update: 02 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ascentage Pharma
  • Class Small molecules
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Atherosclerosis; Glaucoma; Kidney disorders; Osteoarthritis

Most Recent Events

  • 24 Apr 2017 Pharmacodynamics data from a preclinical study in Osteoarthritis released by UNITY Biotechnology
  • 24 Apr 2016 Ascentage Pharma and UNITY Biotechnology enter into a worldwide collaboration to develop senolytic treatments for age-related diseases
  • 24 Apr 2016 Preclinical trials in Atherosclerosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top